VA awards $2.6M contract for pharmaceuticals, highlighting potential for significant patient impact

Contract Overview

Contract Amount: $2,635,334 ($2.6M)

Contractor: Novartis Pharmaceuticals Corporation

Awarding Agency: Department of Veterans Affairs

Start Date: 2025-02-07

End Date: 2026-02-06

Contract Duration: 364 days

Daily Burn Rate: $7.2K/day

Competition Type: FULL AND OPEN COMPETITION

Number of Offers Received: 1

Pricing Type: FIRM FIXED PRICE

Sector: Healthcare

Official Description: LUTATHERA & PLUVICTO

Place of Performance

Location: EAST HANOVER, MORRIS County, NEW JERSEY, 07936

State: New Jersey Government Spending

Plain-Language Summary

Department of Veterans Affairs obligated $2.6 million to NOVARTIS PHARMACEUTICALS CORPORATION for work described as: LUTATHERA & PLUVICTO Key points: 1. Contract value suggests a substantial need for specialized pharmaceutical products. 2. The award to a major pharmaceutical corporation indicates a focus on established supply chains. 3. Fixed-price contract structure offers cost certainty for the agency. 4. The relatively short duration may indicate a pilot program or specific supply need. 5. Geographic focus on New Jersey points to regional distribution or manufacturing considerations. 6. The contract's purpose aligns with critical healthcare needs within the VA system.

Value Assessment

Rating: good

The contract value of approximately $2.6 million for a one-year period appears reasonable for specialized pharmaceuticals. Benchmarking against similar contracts for high-value drugs is challenging without more specific product information. However, the award to Novartis, a major player, suggests competitive pricing was likely achieved. The firm fixed-price nature provides budget predictability.

Cost Per Unit: N/A

Competition Analysis

Competition Level: full-and-open

The contract was awarded under full and open competition, indicating that multiple vendors had the opportunity to bid. This process is designed to foster price discovery and ensure the government receives the best value. The fact that it was competed suggests that the VA sought competitive proposals for these pharmaceutical products.

Taxpayer Impact: Full and open competition generally benefits taxpayers by driving down prices through market forces, ensuring that federal dollars are used efficiently.

Public Impact

Veterans will benefit from access to potentially life-saving or critical treatment medications. The services delivered are the provision of specialized pharmaceutical preparations. The geographic impact is primarily within New Jersey, suggesting regional distribution or a facility located there. Workforce implications are likely minimal, primarily related to pharmacy and medical staff administering the medications.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Potential for price fluctuations if market conditions change significantly during the contract term, despite fixed-price structure.
Dependence on a single supplier for critical medications could pose a risk if supply chain issues arise.

Positive Signals

Awarded through full and open competition, suggesting a competitive pricing environment.
Firm fixed-price contract provides cost certainty for the VA.
Contracting with a reputable pharmaceutical manufacturer like Novartis implies a focus on quality and reliability.

Sector Analysis

The pharmaceutical manufacturing sector is a critical component of the healthcare industry, characterized by high research and development costs, stringent regulatory oversight, and significant market concentration. Federal spending in this area often supports the procurement of specialized drugs for specific populations, such as veterans. Comparable spending benchmarks are highly dependent on the specific drugs procured and their therapeutic class.

Small Business Impact

This contract does not appear to have a small business set-aside. Given the nature of pharmaceutical manufacturing and the specific products likely involved (LUTATHERA & PLUVICTO), it is probable that only a limited number of large, specialized firms could meet the requirements. Subcontracting opportunities for small businesses are unlikely to be significant in this direct procurement.

Oversight & Accountability

The Department of Veterans Affairs has established oversight mechanisms for pharmaceutical contracts, including quality assurance checks and performance monitoring. Accountability is maintained through the contract terms and conditions, with potential for remedies if performance standards are not met. Transparency is facilitated by the contract award data, though specific product details may be proprietary.

Related Government Programs

Department of Veterans Affairs Pharmaceutical Prime Vendor Program
Department of Defense Tricare Pharmacy Program
National Institutes of Health Research Grants

Risk Flags

High-cost specialized medication
Potential supply chain vulnerability
Dependence on specific patient eligibility criteria

Frequently Asked Questions

What is this federal contract paying for?

Department of Veterans Affairs awarded $2.6 million to NOVARTIS PHARMACEUTICALS CORPORATION. LUTATHERA & PLUVICTO

Who is the contractor on this award?

The obligated recipient is NOVARTIS PHARMACEUTICALS CORPORATION.

Which agency awarded this contract?

Awarding agency: Department of Veterans Affairs (Department of Veterans Affairs).

What is the total obligated amount?

The obligated amount is $2.6 million.

What is the period of performance?

Start: 2025-02-07. End: 2026-02-06.

What are LUTATHERA and PLUVICTO, and what is their typical use case within the VA healthcare system?

LUTATHERA (lutetium Lu 177 vipivotide tetraxetan) and PLUVICTO (lutetium Lu 177 vipivotide tetraxetan) are radioligand therapies used to treat certain types of advanced prostate cancer. Specifically, they are indicated for patients with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer (mCRPC) who have received prior treatment. Within the VA healthcare system, these drugs would be prescribed to eligible veterans diagnosed with this specific form of advanced prostate cancer, offering a targeted treatment option that delivers radiation directly to cancer cells expressing PSMA. The VA's procurement of these high-cost, specialized therapies underscores its commitment to providing advanced cancer care to its patient population.

How does the $2.6 million contract value compare to historical VA spending on similar radioligand therapies?

Comparing the $2.6 million contract value to historical VA spending on similar radioligand therapies requires access to detailed historical procurement data for LUTATHERA and PLUVICTO or comparable treatments. Radioligand therapies are typically high-cost, specialized treatments, often administered in limited quantities due to their complexity and patient-specific nature. A $2.6 million award for a one-year duration suggests a significant but potentially focused procurement. Without specific historical data points for these exact drugs or very similar ones (e.g., other PSMA-targeted therapies), it's difficult to establish a precise benchmark. However, given the nature of these advanced treatments, this award appears to be within a plausible range for providing such critical care to a segment of the veteran population.

What are the primary risks associated with this contract, and how are they mitigated?

The primary risks associated with this contract include supply chain disruptions for these specialized pharmaceuticals, potential for underutilization if patient eligibility or demand is lower than anticipated, and the inherent high cost of radioligand therapies. Mitigation strategies likely involve the VA's robust supply chain management processes, close collaboration with Novartis to ensure consistent delivery, and careful patient selection protocols based on clinical guidelines. The firm fixed-price nature mitigates budget overrun risks for the VA. Furthermore, the full and open competition process helps ensure that the VA is working with a capable and reliable supplier, reducing the risk of contractor default.

What is the expected impact of this contract on veteran healthcare outcomes, particularly for prostate cancer patients?

This contract is expected to have a direct and potentially significant positive impact on the healthcare outcomes for eligible veterans suffering from advanced prostate cancer. By ensuring a reliable supply of LUTATHERA and PLUVICTO, the VA is enabling access to cutting-edge treatments that have shown efficacy in improving survival rates and quality of life for patients with metastatic castration-resistant prostate cancer. This procurement signifies the VA's dedication to offering advanced oncological therapies, thereby improving the standard of care and potentially extending the lives of veterans battling this serious disease.

What does the contract's duration of 364 days imply about the VA's procurement strategy for these pharmaceuticals?

The contract duration of 364 days, just shy of a full year, suggests a strategic approach by the VA. It could indicate that this is an initial procurement for these specific drugs, allowing the agency to assess demand, utilization, and supplier performance over a defined period before committing to longer-term agreements. Alternatively, it might align with specific budgetary cycles or the anticipated treatment duration for a cohort of patients. This shorter term also provides flexibility to re-evaluate the market and potentially re-compete the contract if pricing or product availability changes significantly, ensuring continued value for taxpayer dollars.

Industry Classification

NAICS: Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing

Product/Service Code: MEDICAL/DENTAL/VETERINARY EQPT/SUPP

Competition & Pricing

Extent Competed: FULL AND OPEN COMPETITION

Solicitation Procedures: SUBJECT TO MULTIPLE AWARD FAIR OPPORTUNITY

Offers Received: 1

Pricing Type: FIRM FIXED PRICE (J)

Evaluated Preference: NONE

Contractor Details

Parent Company: Advanced Accelerator Applications USA Inc

Address: 59 ROUTE 10, EAST HANOVER, NJ, 07936

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Manufacturer of Goods, Not Designated a Small Business, Special Designations, U.S.-Owned Business

Financial Breakdown

Contract Ceiling: $2,635,334

Exercised Options: $2,635,334

Current Obligation: $2,635,334

Contract Characteristics

Commercial Item: COMMERCIAL PRODUCTS/SERVICES

Parent Contract

Parent Award PIID: 36F79720D0180

IDV Type: FSS

Timeline